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Background: The study of endogenous insulin secretion may provide relevant insight into the comparison of the
natural history of adult onset latent autoimmune diabetes (LADA) with types 1 and 2 diabetes mellitus. The aim of
this study was to compare the results of the C-peptide response to mixed-meal stimulation in LADA patients with
different disease durations and subjects with type 2 and adult-onset type 1 diabetes.
Methods: Stimulated C-peptide secretion was assessed using the mixed-meal tolerance test in patients with LADA
(n = 32), type 1 diabetes mellitus (n = 33) and type 2 diabetes mellitus (n = 30). All patients were 30 to 70 years old
at disease onset. The duration of diabetes in all groups ranged from 6 months to 10 years. The recruitment strategy
was predefined to include at least 10 subjects in the following 3 disease onset categories for each group: 6 to
18 months, 19 months to 5 years and 5 to 10 years.
Results: At all time-points of the mixed-meal tolerance test, patients with LADA had a lower stimulated C-peptide
response than the type 2 diabetes group and a higher response than the type 1 diabetes group. The same results
were found when the peak or area under the C-peptide curve was measured. When the results were stratified by
time since disease onset, a similar pattern of residual insulin secretory capacity was observed.
Conclusions: The present study shows that the magnitude of stimulated insulin secretion in LADA is intermediate
between that of type 1 and type 2 diabetes mellitus.
Keywords: Latent autoimmune diabetes in adults, Type 1 diabetes mellitus, Type 2 diabetes mellitus, Insulin
secretion, C-peptideBackground
The increased frequency of insulin treatment in adult
patients with latent autoimmune diabetes (LADA) is a
result of an accelerated pancreatic beta-cell loss due to
autoimmune damage [1]. The measurement of the en-
dogenous insulin secretion may provide relevant insight
into the comparison of the natural history of LADA with
the natural histories of types 1 and 2 diabetes; however,
limited data are available regarding fasting or stimulated* Correspondence: didacmauricio@gmail.com
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is currently accepted as the reference outcome for asses-
sing beta-cell secretory response in trials studying the pre-
vention of beta-cell loss in established autoimmune
diabetes [9]. In addition, no studies have assessed the insu-
lin secretory response using the standardised mixed-meal
tolerance test (MMTT) in patients with LADA. Therefore,
the aim of our study was to assess the stimulated C-
peptide response in LADA patients with different disease
durations and to compare the results to those of subjects
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Participants and clinical data
In this cross-sectional study, we enrolled 32 subjects
with LADA, 33 subjects with type 1 and 30 subjects with
type 2 diabetes mellitus. A total of 11 study subjects, 4
with LADA and 7 with type 1 diabetes, were recruited in
Hospital de Sant Pau. All other subjects were included
at Hospital Arnau de Vilanova. All study subjects were
30 – 70 years old at the time of diagnosis. Type 1 and
type 2 diabetes mellitus were diagnosed according to the
standard criteria as described previously [8], and LADA
was defined as patients aged 30 – 70 years at the diagno-
sis of diabetes who did not require insulin for at least
6 months after diagnosis, with glutamic acid decarboxyl-
ase (GAD) autoantibody (GADAb) or tyrosine phosphat-
ase autoantibody (IA-2Ab) positivity. The study was
initially part of the Action LADA project that was ex-
tended locally for an additional period of 3 years [10].
The study protocol was designed to recruit 10 subjects
in the following disease duration categories for each
group: 6 – 18 months, 19 months – 5 years, and 5 –
10 years from diagnosis. This number of subjects was
established based on previous studies that yielded clear
differences when this sample size was used to compare
LADA and type 2 diabetes [1,2]. Thus, at least 30 pa-
tients of each diabetes type were included. None of the
subjects had impaired kidney function, liver disease or
any other condition known to interfere with the C-
peptide response. Patients were included consecutively
after they signed a written informed consent document.
The study protocol was approved by the local Ethics
Committee of the two centers where patients were
recruited, i.e. Hospital de Sant Pau (Barcelona) and Hos-
pital Arnau de Vilanova (Lleida).
For each subject, age, sex, weight, height, body mass
index, and disease duration were obtained as recently
described [8]. The time to start of insulin was calculated
as the time between the date of diagnosis and the date
of the first insulin treatment. In addition, glucose and
HbA1c levels were tested using standard laboratory as-
says. A detailed description of the methods was recently
published [8].
Antibody measurements
Antibodies to islet cell antigens (GADA65 and IA-2) were
measured with two commercially available ELISA kits:
GAD65 Autoantibody ELISA and IA-2 Autoantibody
ELISA (both from DRG Diagnostic, Marburg, Germany),
as previously described [11,12]. Optimal cut-off values for
positivity were set at 5 and 15 U/mL for GADAb and
IA-2Ab, respectively. Both assays showed good per-
formance when tested in the Diabetes Antibody
Standardization Program Workshops. In the Diabetes
Antibody Standardization Program Workshop 2007,sensitivities and specificities were 94% and 97% for
GADAb, respectively, and 66% and 95% for IA-2Ab; in
the Diabetes Antibody Standardization Program Work-
shop 2009, the figures were 82% and 95% for GADAb,
and 60% and 100% for IA-2Ab, respectively.
Mixed meal tolerance test
The test was performed following the same procedures
as those described in the European C-Peptide Trial in
which our group participated [13]. Briefly, after an over-
night fasting period, all study subjects were scheduled to
start the test before 10 a.m. the next morning. Subjects
were asked to withhold any short-acting insulin for at
least 6 hours before the test. The standard meal con-
sisted of 6 ml/kg of a Boost HP drink (Nestle Nutrition,
Vevey, Switzerland); the subjects were given up to
360 ml for up to 5 minutes. C-peptide samples were col-
lected at times −5 and 0 minutes before (the mean of
these two values was taken as the fasting concentration),
and 10, 20, 30, 60, 90 and 120 minutes after the final in-
take of the mixed-meal.
C-peptide was measured by a chemiluminescence assay
(Immulite 2000, Siemens Medical Solutions Diagnostics,
LA, USA), with reference values of 0.30 – 2.4 nmol/l
(intra and interassay coefficients of variation were less
than 5%). The lower detection limit was 0.03 nmol/l. Any
value below the lower detection limit was arbitrarily
assigned a concentration of 0.029 nmol/l.
Statistical analysis
Continuous variables are expressed as the mean (± SD)
or the median (interquartile range ([IQR]) where appro-
priate. Categorical variables are described using the ab-
solute and relative frequencies. Variables with a skewed
distribution were log-transformed before analysis. Com-
parisons between groups were performed using the non-
parametric Mann–Whitney U test for numerical variables
and the χ2 test for percentages. The area under the curve
of C-peptide (AUCCP) was computed from all timed col-
lections using the trapezoidal rule [9]. The analyses of the
AUCCP and peak C-peptide were adjusted for sex, body
mass index, age, duration of diabetes, fasting glucose,
HbA1c and basal C-peptide. The results were considered
to be statistically significant if the two-sided p-value was
less than 0.05. All analyses were performed with SPSS for
Windows version 15.0 (Chicago, USA).
Results
The clinical characteristics of the study groups are
shown in Table 1. There were no differences in terms of
age, sex distribution and disease duration among the 3
study groups. As already found in previous studies in
our setting [8], type 2 diabetic subjects demonstrated
better glycemic control than patients with LADA and
Table 1 Clinical characteristics and C-peptide stimulated secretion of the 3 study groups
Type 1 diabetes Type 2 diabetes LADA pa pb
Women, n (%) 17 (51.5%) 9 (30%) 11 (34.4%) 0.166 0.715
Age, years 46.9 (10.6) 53.7 (12.9) 49.6 (10.6) 0.170 0.260
Disease duration, monthsc 31 [12–56] 31 (10 – 83) 38.5 [13.5 – 59] 0.618 0.897
BMI, kg/m2 24.7 (4.2) 30.1 (5.5) 27.9 (4.8) 0.004 0.110
Fasting glucose, mmol/l 9.0 (3.49) 7.44 (1.92) 8.84 (3.45) 0.929 0.147
HbA1c, % 7.5 (1.4) 6.9 (1.0) 8.3 (2.4) 0.265 0.012
HbA1c, mmol/mol 58.4 (15.5) 52.2 (11.4) 67.6 (26.7)
Insulin treatment, n (%) 33 (100%) 8 (26.7%) 20 (62.5%) <0.001 0.005
Sulphonylurea treatment, n (%) - 8 (20%) 5 (15.6%) - 0.652
Categories, n 0.867 0.765
6 – 18 m 10 10 10
19 m – 5 years 12 10 10
5 – 10 years 11 10 12
AUC C-peptide, nmol/ld 41.3 (46.4) 275.5 (121.2) 140.8 (102.2) <0.001 <0.001
19.2 (16.8 – 54.9) 245.1 (182.6 – 370.8) 112.1 (54.6 – 231.2)
Peak C-peptide, nmol/lc,d 0.45 (0.50) 3.01 (1.29) 1.50 (1.05) <0.001 <0.001
0.16 (0.16 – 0.60) 2.54 (2.18 – 3.67) 1.44 (0.68 – 2.32)
ap value for comparisons between type 1 diabetes and LADA; bp value for comparison between type 2 diabetes and LADA; cdistributed variables; dpeak and AUC
C-peptide results are given as mean (SD) and also as median (IQR).
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treatment was higher in LADA subjects than in type 2
diabetic subjects.
Concerning treatment of hyperglycemia, insulin treat-
ment was more frequent in LADA than in type 2 diabetes
(62.5% vs. 26.7; p = 0.005) (Table 1). The distribution of
the number of insulin-treated type 2 diabetic subjects ac-
cording to disease duration was 2, 3 and 3 in categories
6 –18 months, 19 months – 5 years, and 5 – 10 years, re-
spectively. The corresponding distribution of insulin treat-
ment in patients with LADA was 5, 6 and 9 in disease
duration categories 6 –18 months, 19 months – 5 years,
and 5 – 10 years, respectively. The frequency of sulphony-
lurea drug use was similar in patients with type 2 diabetes
and LADA (not significantly different). Six type 2 diabetic
subjects were under sulphonylureas, all with a disease dur-
ation longer than 5 years. Five patients with LADA were
under sulphonylurea treatment (3 in the disease duration
category 19 months – 5 years, and 2 in the duration cat-
egory 5 – 10 years). Only one patient with LADA was
treated with sitagliptin, without any other study subjects
treated with a dipeptidylpeptidase – 4 inhibitor.
Subjects with LADA showed a capacity of stimulated C-
peptide secretion that is intermediate between types 1 and
2 diabetic patients, both in terms of the peak secretion
and the AUCCP (Table 1). In LADA, these measures of
insulin secretion were significantly lower than in type 2
diabetic subjects and significantly higher than in type 1
subjects. These differences remained unchanged afteradjusting for other confounding variables as age, sex,
body mass index, HbA1c and glucose. This lower residual
insulin secretion capacity was also confirmed when sub-
jects were stratified by disease duration (Figure 1, and
Additional files 1 and 2). Detailed results for AUCCP and
peak C-peptide secretion according to disease duration
are shown in Additional files 1 and 2. Most measures of
C-peptide secretion were significantly different between
patients with LADA and those with type 1 or type 2 dia-
betes; the only exception was the comparison between the
sub-analysis of the peak C-peptide and AUCCP of LADA
and type 2 diabetes in subjects with shorter diabetes dur-
ation (6 to 18 months).
Concerning the stimulated C-peptide in insulin-treated
patients, those with LADA showed a lower response that
was lower than that of type 2 diabetic subjects. Patients
with LADA showed an AUCCP (102.4 ± 112.3 nmol/l)
and peak C-peptide (1.25 ± 1.08 nmol/l) that were below
those of type 2 diabetes patients (AUCPP: 200.1 ±
91.7 nmol/l; peak C-peptide: 2.23 ± 0.85 nmol/l) (p = 0.043
and p = 0.038, respectively). This finding is specially
relevant considering that the disease duration of this 2
sub-groups of insulin-treated patients is not different
(type 2 diabetes: 45.6 ± 42.8 months; LADA: 46 ±
32.2 months). Concerning non-insulin treated patients,
those with LADA also had a lower C-peptide response,
with an AUCCP (174.7 ± 74.8 nmol/l) and peak C-
peptide (1.92 ± 0.87 nmol/l) in comparison with type 2
diabetic patients (AUCPP: 302.9 ± 120.5 nmol/l; peak
Figure 1 The results of the mixed-meal tolerance test (panel a: area under the curve; panel b: peak C-peptide) of the different study
groups (33 with type 2, 32 with LADA and 30 with type 2 diabetes), stratified according to the duration of diabetes mellitus.
Footnote: Triangles, circles and squares denote mean values with 95% CI of C-peptide in type 1 diabetes, type 2 diabetes and LADA, respectively. The
differences between LADA and type 1 and type 2 diabetes are statistically significant except for the comparison of the peak and AUCCP of LADA and
type 2 diabetes in subjects with a shorter diabetes duration (6 to 18 months). The number of patients treated with insulin was 8 in the group of type 2
diabetes and 20 in the group of LADA. For further details, see Table 1, and Additional files 1 and 2.
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respectively).
Discussion
The current findings clearly show that subjects with
LADA, as defined in the Action LADA, have a different
capacity of meal-stimulated insulin secretion at different
disease stages. This is the first study to use the standar-
dised MMTT to assess the residual stimulated insulin
secretion in LADA patients based on different periods of
disease duration.
The current findings are consistent with some previ-
ous studies in the literature. The fasting C-peptide re-
sults are similar to the values found in previous studies
[3,4,6,8]. The current differences in fasting C-peptide
confirm our previous findings in a larger population
sample [8]. Also, the results show a consistent lower
stimulated C-peptide secretion in those patients with
LADA with or without insulin-treatment with respect
to the respective counterparts with type 2 diabetes.
Hosszúfalusi et al. also described the same initial pattern
of differences with type 1 and type 2 diabetes; however,
C-peptide secretion in patients with longer-duration
LADA overlapped with the values for type 2 diabetic pa-
tients. In addition, over 6 years of follow-up, two pro-
spective cohort studies with subjects of Asian origin
consistently showed a more rapid loss of insulin secre-
tion in LADA, measured as fasting C-peptide, than in
type 2 diabetes [4,6].
However, the most relevant information concerning
residual insulin secretion in patients with LADA comes
from Swedish studies. A study by Carlsson et al. demon-
strated a decreased glucagon- and arginine-stimulated
C-peptide secretion in a small group of LADA patients
when compared to antibody-negative type 2 diabetic
subjects [2]. Previously, the most relevant follow-up data
of stimulated insulin secretion were described in sub-
studies of a Swedish cohort of type 2 diabetic subjects
[1]. In this group glucose- and glucagon-stimulated insu-
lin secretion were clearly different in autoimmune dia-
betes when compared to antibody negative type 2
diabetic patients up to 3 years after diagnosis. A com-
parison with type 1 diabetic subjects demonstrated im-
proved insulin secretion in LADA that subsequently
disappeared after 1 year of follow-up. In addition, data
from a recent Swedish intervention study showed that
during 36 months of follow-up, the glucagon stimulated
C-peptide response decreased in patients with conven-
tionally treated LADA [7].
The main limitation of this study is its cross-sectional
design. Ideally, the characterisation of the natural history
of insulin secretion in LADA subjects would be analysed
in prospective follow-up studies. Based on the results of
the current study, a prospective characterisation of thetime-course of the loss of the insulin secretory capacity
and the comparison with other diabetes types would re-
quire a multi-centre study with long-term follow-up.
Another limitation is the number of subjects studied;
however, this is the first study to use the reference
MMTT method to compare the stimulated C-peptide
response in LADA to the responses in types 1 and 2 dia-
betes on different stages of disease duration.
Conclusions
The present study shows that the stimulated insulin se-
cretion capacity in LADA is intermediate between that
of types 1 and 2 diabetes. This finding provides new data
and further contributes to the characterisation of the
natural history of LADA.
In addition, the study results may be helpful for future
intervention trials aimed at preserving the residual insu-
lin secretory capacity in subjects with autoimmune
diabetes. Potential future prevention trials should be de-
signed accordingly.
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